News Sonnet BioTherapeutics Holdings, Inc.

Equities

SONN

US83548R3030

Market Closed - Nasdaq Other stock markets 03:59:53 2024-05-15 pm EDT			5-day change	1st Jan Change
1.79 ^USD	-1.10%		+1.70%	+2.87%

Mar. 11	Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	MT
Mar. 11	Top Premarket Gainers	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference	May. 03	NE
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy at the AACR 2024 Annual Meeting	Mar. 20	AQ
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	Mar. 11	MT
Top Premarket Gainers	Mar. 11	MT
Sonnet BioTherapeutics Holdings, Inc. Announces First Phase 1b/2a Clinical Trial of SON-080	Mar. 11	CI
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers	Mar. 01	AQ
Chardan Cuts PT on Sonnet BioTherapeutics to $30 From $75 to Reflect Higher Projected Future Share Count, Keeps Buy Rating	Feb. 15	MT
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update	Feb. 15	AQ
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 14	CI
North American Morning Briefing : Stock Futures -2-	Feb. 09	DJ
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy	Dec. 22	AQ
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	Dec. 20	DJ
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update	Dec. 15	AQ
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 14	CI
North American Morning Briefing : Traders Await -2-	Dec. 13	DJ
Ladenburg Thalmann Starts Sonnet BioTherapeutics Holdings With Buy Rating, $7 Price Target	Nov. 27	MT
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering	23-10-26	AQ
Sector Update: Health Care Stocks Retreating Late Afternoon	23-10-25	MT
Top Midday Decliners	23-10-25	MT
Top Premarket Decliners	23-10-25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sonnet BioTherapeutics Holdings, Inc.

Equities

SONN

US83548R3030

Summary

Filters